ATLAS™ Sternal Repair Matrix is intended for challenging sternal fusion cases and IKON™ Allograft Surgical Matrix assists with soft tissue repair in high-risk patients MTF Biologics and Kolosis BIO Launch Two New Allografts to Advance Cardiac Surgery EDISON, N.J. & SALT LAKE CITY–(BUSINESS WIRE)–MTF Biologics, a global nonprofit organization that […]
Other News
With CCTA Poised to Transform PCI Planning, SCAI/SCCT Publish Expert Opinion Document
WASHINGTON—A new expert opinion document jointly released by the Society for Cardiovascular Angiography and Interventions (SCAI) and the Society of Cardiovascular Computed Tomography (SCCT) presents a comprehensive framework for using coronary computed tomography angiography (CCTA) to guide percutaneous coronary intervention (PCI). Published in JSCAI, “Coronary Computed Tomography Angiography to Guide […]
Cardiawave Announces Positive 12-Month Results from Its “Valvosoft® FIM Study” and “Valvosoft® Pivotal Study” for the Treatment of Severe Symptomatic Aortic Stenosis (sSAS)
At the EuroPCR 2025 Congress – Paris Results confirm the promise of non-invasive ultrasound therapy (NIUT) previously observed in earlier clinical studies. 91% of patients were free of major adverse cardiac events (MACE) at 30 days (achieving the primary endpoint objective MACE ≤ 25%). 85% of patients experienced an improvement or stabilization […]
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
PARIS–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated […]
Phraxis Announces FDA Approval of EndoForce™ Connector for Endovascular Venous Anastomosis, Advancing Dialysis Access Innovation
MINNEAPOLIS, May 22, 2025 /PRNewswire/ — Phraxis Inc., a Minneapolis-based medical device company, marks a major milestone with FDA approval of the EndoForce™ Connector for Endovascular Venous Anastomosis (EndoForce™) — a pivotal development in the evolution of dialysis access technology….
OMRON Healthcare Evolves the Blood Pressuring Experience with AI-powered AFib detection
Number one doctor and pharmacist-recommended blood pressure monitor brand introduces blood pressure monitors with OMRON Intellisense™ AFib HOFFMAN ESTATES, Ill., May 21, 2025 /PRNewswire/ — Heralding an evolution of the blood pressure monitoring experience, heart health leader OMRON…
New Study Finds RapidAI Significantly Outperforms Viz.ai in Detecting Medium Vessel Occlusions in Stroke Patients
RapidAI detects 33% more MeVOs than Viz.ai, with new real-world data presented at ESOC highlighting superior accuracy and deeper clinical insights San Mateo, Calif. — May 21, 2025 // RapidAI, the gold standard and global leader in neurovascular AI-based clinical decision support and enterprise radiology solutions, today announced new study […]
Revalesio Presents Additional Analyses from the Phase 2 RESCUE Clinical Trial for RNS60 in Acute Ischemic Stroke
TACOMA, Wash., May 21, 2025 /PRNewswire/ — Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced data from a post hoc analysis of its completed Phase 2 RESCUE clinical trial, showing that ischemic stroke…
MultiFunctional Imaging To Present New Data On A Back-To-Back 15-minute Rest-Stress Myocardial Perfusion Imaging Protocol At SNMMI 2025
SOUTH OGDEN, UT – May 21, 2025 –- MultiFunctional Imaging LLC (MFI) today announced the upcoming oral presentation on using the mfiVerseä software for immediate back-to-back rest-stress cardiac PET scanning with F18 flurpiridaz for the evaluation of patients with known or suspected heart disease. The Society of Nuclear Medicine and […]
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025
SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia’s CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025.
